<DOC>
	<DOCNO>NCT00893035</DOCNO>
	<brief_summary>The primary objective study evaluate prediction late toxicity radiation induce CD8 T-lymphocyte apoptosis</brief_summary>
	<brief_title>Evaluation Apoptotic Test Predicting Late Toxicities After Radiotherapy Breast Prostate Cancer Patients</brief_title>
	<detailed_description>The two cancer site concern trial intermediate risk prostate cancer treat conformational radiotherapy without intensity modulation , breast cancer patient treat adjuvant radiotherapy breast conservative surgery patient age 60 year age . The identification 5 % patient risk severe toxicity allow deliver high dose radiotherapy among 95 % patient low risk severe late complication .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion Criteria prostate cancer patient : localised prostate cancer , histologically proven Absence metastasis ( M0 ) : normal bone scintigraphy Absence radiological lymph node invasion ( N0 ) . Clinical Stage : T ≥ T1cT2a &lt; T3b Or T1b c PSA ≤ 10 ng/ml . Or T1b c Gleason ≥ 6 PSA &lt; 30 ng/ml . Signs symptom accord NCI/CTC v3.0 &lt; grade 2 ECOG Performance status ≤ 1 Absence hip prothesis Absence de endopenian stent Patient age &gt; 18 &lt; 80 Patient affiliate social security Written inform consent , date sign Exclusion Criteria prostate cancer patient : Antecedents invasive cancer ( unless treat 5 year ago without evolution ) except basocellular carcinoma positive biopsy seminal vesicle PSA ≥ 30 ng/ml two successive dosage Previous pelvic irradiation Previous radical prostatectomy cancer Patients another systemic disease ( cardiovascular , renal , hepatic , pulmonary embolism , etc . ) non stabilise generalised sclerodermitis . Patients know HIV seropositive ( specific test necessary define eligibility ) Known homozygote ATM ( Ataxy telangiectasy ) mutation Impossibility correct follow ( social family geographical reason ) Patients incapable provide consent , protect major , vulnerable person Patients participate clinical trial Inclusion Criteria breast cancer patient : Breast Conservative surgery Non metastatic , M0 negative surgical margin T1 , T2 ; negative sentinel lymph node N0 , N1 N2 . Signs symptom accord NCI/CTC v3.0 &lt; grade 2 Patient age 18 year less 60 60 indication boost irradiation . Patient affiliate social security Written inform consent , date sign Exclusion Criteria breast cancer patient : Metastatic patient Bilateral breast cancer ( concomitant previous ) except situ T4 N3 treat mastectomy Patients chemotherapy neoadjuvant hormonotherapy Patients previous cancer within last 5 year EXCEPT basocellular carcinoma skin situ cancer uterus . Patients another systemic disease ( cardiovascular , renal , hepatic , pulmonary embolism , etc . ) non stabilise generalised sclerodermia . Pregnant breast feed woman Patients know HIV seropositive ( specific test necessary define eligibility ) Known homozygote ATM ( Ataxy telangiectasy ) mutation Impossibility correct follow ( social family geographical reason ) Patients incapable provide consent , protect major , vulnerable person Patients participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Late side effect</keyword>
	<keyword>Predictive assay</keyword>
</DOC>